This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pace, J. L.
Right arrow Articles by Kaniga, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pace, J. L.
Right arrow Articles by Kaniga, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2003, p. 3602-3604, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3602-3604.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of TD-6424 against Staphylococcus aureus

John L. Pace, Kevin Krause, Deborah Johnston, Dmitri Debabov, Terry Wu, Lesley Farrington, Cassie Lane, Deborah L. Higgins, Burt Christensen, J. Kevin Judice,{dagger} and Koné Kaniga*

Theravance, Inc., South San Francisco, California 94080

Received 30 May 2003/ Returned for modification 21 July 2003/ Accepted 25 August 2003


arrow
ABSTRACT
 
TD-6424, a rapidly bactericidal agent with multiple mechanisms of action, is more potent in vitro and more rapidly bactericidal than currently available agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. TD-6424 produces a postantibiotic effect with a duration of 4 to 6 h against these organisms. The results suggest potential efficacy against susceptible and resistant strains of S. aureus.


arrow
TEXT
 
Drug-resistant Staphylococcus aureus has become an increasingly important problem for the management of serious infections (2, 3, 6). TD-6424 is a new agent which is rapidly bactericidal for gram-positive bacteria. Its activity is mediated via a pair of biochemically distinct mechanisms. In addition to inhibition of peptidoglycan synthesis, TD-6424 also inhibits the synthesis of phospholipids required for integrity of the bacterial cell membrane (J. L. Pace, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 454, p. 614, 2002). In the present study, the susceptibilities of methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), and glycopeptide-intermediate S. aureus (GISA) to TD-6424, vancomycin, oxacillin, linezolid, and teicoplanin were evaluated. The bactericidal activities and postantibiotic effects (PAEs) of TD-6424 and vancomycin against MSSA, MRSA, and GISA were also assessed.

S. aureus strains were clinical isolates obtained within the last 4 years from a variety of hospitals in the United States and Europe. Well-characterized S. aureus strains from the American Type Culture Collection (ATCC; Manassas, Va.), the Centers for Disease Control and Prevention (Atlanta, Ga.), and other sources were also used. TD-6424 was obtained from Theravance, and all other agents were obtained from Sigma-Aldrich (St. Louis, Mo.), the U.S. Pharmacopeia (Rockville, Md.), or Hoechst AG (now Aventis; Frankfurt am Main, Germany).

The MIC was determined by the broth microdilution method according to protocol M7-A5 of the NCCLS (5). The minimum bactericidal concentration (MBC) was determined according to protocol M26-A of the NCCLS (4) from the microtiter plates used to determine MICs with a starting inoculum of ~5 x 105 CFU/ml. After a 24-h incubation, the number of survivors from wells with no obvious turbidity was determined by plate counting of 10-µl samples. The bactericidal activity was determined by a time-kill assay (4) in 10 ml of Mueller-Hinton broth with a starting inoculum of ~106 CFU/ml of log-phase cultures. At regular intervals, bacteria were enumerated by plate counting from 200 µl samples. For both MBC and time-kill assays, bactericidal activity was defined as a >=3-log10 decrease in the number of CFU per milliliter within 24 h. The limit of detection was 10 CFU/ml.

The durations of the PAEs were determined according to a published protocol (1) with the following modifications. In brief, the 20-ml starting inoculum of ~106 CFU/ml was exposed to the MIC of the compound for 1 h at 37°C. Bacteria were then removed from the antibiotic-containing medium by centrifugation and washed with saline to remove residual antibiotic. Bacteria were resuspended in 20 ml of prewarmed Mueller-Hinton broth and incubated with shaking. Plate counts were performed from 100-µl samples diluted appropriately at hourly intervals to determine the time at which a 1-log10 increase in CFU per milliliter occurred after antibiotic removal. The duration of PAE was calculated as the number of hours until return to log-phase growth of treated bacteria minus the time for return of control bacteria (no antibiotic but treated identically) to log-phase growth.

Susceptibility testing. TD-6424 was highly active against MSSA. The MICs of TD-6424 for these organisms were generally lower than those of vancomycin, oxacillin, linezolid, and teicoplanin (Table 1). The MICs of TD-6424 for 47 strains of MSSA ranged from 0.12 to 2 µg/ml, and the MIC at which 90% of organisms were inhibited (MIC90) was 1 µg/ml. The MIC of TD-6424 for ATCC 13709 was 0.5 µg/ml, compared to 0.5 µg/ml for nafcillin, gentamicin, and oxacillin, 1 µg/ml for vancomycin and teicoplanin, and 4 µg/ml for linezolid. TD-6424 was more active against MRSA than were vancomycin, oxacillin, linezolid, and teicoplanin (Table 1). The MICs of TD-6424 for 128 strains of MRSA ranged from <=0.06 to 2 µg/ml, and the MIC90 was 1 µg/ml. The MIC of TD-6424 for ATCC 33591 was 0.5 µg/ml, compared to 1 µg/ml for vancomycin, 2 µg/ml for teicoplanin, linezolid, and gentamicin, and 128 µg/ml for nafcillin and oxacillin. TD-6424 (MIC 2 µg/ml) was more active than vancomycin, teicoplanin, nafcillin, and oxacillin (all MICs, 8 µg/ml) against a well-characterized strain of GISA (HIP 5836).


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro activities of TD-6424 and comparator antibiotics against MRSA and MSSA

Bactericidal activity. The MBCs of TD-6424 for MSSA (ATCC 13709), MRSA (ATCC 33591), and GISA (HIP 5836) were 2, 4, and 4 µg/ml, respectively; the corresponding values for vancomycin were 2, 4, and 8 µg/ml, and those for nafcillin were 0.5, >128, and 128 µg/ml. The results of time-kill assays demonstrated the rapid, concentration-dependent bactericidal activity of TD-6424. Results for MSSA indicated that TD-6424 (4 µg/ml) reduced the initial inoculum from log10 6.22 ± 0.08 CFU/ml to log10 3.36 ± 0.28 CFU/ml within 4 h after administration (Fig. 1A). Generally, similar results were obtained for nafcillin (4 µg/ml). With vancomycin (4 µg/ml), the initial inoculum was decreased by only about 1 log10 at 4 h. Linezolid (8 µg/ml) exhibited the least bactericidal activity in this assay. Results with TD-6424 for MRSA were generally similar to those for MSSA (Fig. 1B): TD-6424 at 8 and 32 µg/ml reduced the initial inoculum from log10 6.05 ± 0.08 CFU/ml to log10 4.87 ± 0.05 and 1.26 ± 0.26 CFU/ml, respectively, within 4 h. Vancomycin at 8 µg/ml exhibited much slower bactericidal activity, and linezolid at 16 µg/ml had almost no bactericidal activity against this organism. TD-6424 at 8, 16, and 32 µg/ml was also rapidly bactericidal against GISA (Fig. 1C). By 4 h, the 8- and 32-µg/ml concentrations had reduced the initial inoculum from log10 5.76 ± 0.07 to 3.21 ± 0.12 and 0.98 ± 0.02 CFU/ml, respectively. Linezolid at 8 µg/ml reduced the initial inoculum from log10 5.76 ± 0.07 CFU/ml to log10 2.73 ± 0.08 CFU/ml by 4 h, and vancomycin at 32 µg/ml decreased it from log10 5.76 ± 0.07 CFU/ml to log10 4.82 ± 0.02 CFU/ml over this period.



View larger version (12K):
[in this window]
[in a new window]
  		FIG. 1. Time-kill curves for MSSA (ATCC 13709) (A), MRSA (ATCC 33591) (B), and GISA (HIP 5836) (C). (A) Vancomycin at 4 times the MIC ({blacklozenge}), nafcillin at 4 times the MIC ({blacksquare}), linezolid at 4 times the MIC ({blacktriangleup}), and TD-6424 at 4 times the MIC ({triangleup}); (B) vancomycin at 8 times the MIC ({blacklozenge}), linezolid at 8 times the MIC ({blacktriangleup}), and TD-6424 at 8 ({triangleup}) and 32 ({blacksquare}) times the MIC; (C) linezolid at 4 times the MIC ({blacktriangleup}), vancomycin at 4 times the MIC ({blacklozenge}), and TD-6424 at 4 ({triangleup}), 8 ({blacksquare}), and 16 ({square}) times the MIC. *, bacterial growth control. The nafcillin MIC was 1 µg/ml for ATCC 13709. Vancomycin MICs were 1, 1, and 8 µg/ml for ATCC 13709, ATCC 33591, and HIP 5836, respectively; the corresponding values were 2, 2, and 2 µg/ml for linezolid and 1, 1, and 2 µg/ml for TD-6424.

PAE. TD-6424 had long durations (>=4 h) of PAE against MSSA, MRSA, and GISA (Table 2). Vancomycin had substantially shorter PAEs, whereas nafcillin did not generate a PAE against the MSSA strain in this assay.


View this table:
[in this window]
[in a new window]
  		TABLE 2. PAE for TD-6424 and comparator antibiotics

In summary, TD-6424 is highly active against MSSA, MRSA, and GISA and has significant bactericidal activity and a long PAE against these organisms. The in vitro properties of TD-6424 suggest that it may be effective in infections caused by both susceptible and resistant strains of S. aureus.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080. Phone: (650) 808-6158. Fax: (650) 808-6186. E-mail: kkaniga{at}theravance.com. Back

{dagger} Present address: Department of Medicinal Chemistry, Genentech, Inc., South San Francisco, CA 94080. Back


arrow
REFERENCES
 
    1
  1. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md.
    2. 2
  2. Hiramatsu, K., L. Cui, M. Kuroda, and T. Ito. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 9:486-493.[CrossRef][Medline]
    3. 3
  3. Maranan, M. C., B. Moreira, S. Boyle-Vavra, and R. S. Daum. 1997. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect. Dis. Clin. N. Am. 11:813-849.[CrossRef][Medline]
    4. 4
  4. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    5. 5
  5. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved guideline 5th ed., M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    6. 6
  6. Panlilio, A. L., D. H. Culver, R. P. Gaynes, S. Banerjee, T. S. Henderson, J. S. Tolson, and W. J. Martone. 1992. Methicillin-resistant Staphylococcus aureus in U. S. hospitals, 1975-1991. Infect. Control. Hosp. Epidemiol. 13:582-586.[Medline]

Antimicrobial Agents and Chemotherapy, November 2003, p. 3602-3604, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3602-3604.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Lunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., Benton, B. M. (2009). Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II. Antimicrob. Agents Chemother. 53: 3375-3383 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Hegde, S. S., Difuntorum, S., Skinner, R., Trumbull, J., Krause, K. M. (2009). Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 63: 763-766 [Abstract] [Full Text]  
  • Pankuch, G. A., Appelbaum, P. C. (2009). Postantibiotic Effects of Telavancin against 16 Gram-Positive Organisms. Antimicrob. Agents Chemother. 53: 1275-1277 [Abstract] [Full Text]  
  • Lubenko, I. Yu., Strukova, E. V., Smirnova, M. V., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H., Firsov, A. A. (2008). Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 62: 1065-1069 [Abstract] [Full Text]  
  • Wong, S. L., Barriere, S. L., Kitt, M. M., Goldberg, M. R. (2008). Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 62: 780-783 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62: 116-121 [Abstract] [Full Text]  
  • Krause, K. M., Renelli, M., Difuntorum, S., Wu, T. X., Debabov, D. V., Benton, B. M. (2008). In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 2647-2652 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 2383-2388 [Abstract] [Full Text]  
  • Barcia-Macay, M., Mouaden, F., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F. (2008). Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 61: 1288-1294 [Abstract] [Full Text]  
  • Hegde, S. S., Reyes, N., Skinner, R., Difuntorum, S. (2008). Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 61: 169-172 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Jansen, W. T. M., Verel, A., Verhoef, J., Milatovic, D. (2007). In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe. Antimicrob. Agents Chemother. 51: 3420-3424 [Abstract] [Full Text]  
  • Odenholt, I., Lowdin, E., Cars, O. (2007). Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 51: 3311-3316 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  
  • Reyes, N., Skinner, R., Benton, B. M., Krause, K. M., Shelton, J., Obedencio, G. P., Hegde, S. S. (2006). Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 462-465 [Abstract] [Full Text]  
  • Leuthner, K. D., Cheung, C. M., Rybak, M. J. (2006). Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 338-343 [Abstract] [Full Text]  
  • Stryjewski, M. E., Chu, V. H., O'Riordan, W. D., Warren, B. L., Dunbar, L. M., Young, D. M., Vallee, M., Fowler, V. G. Jr., Morganroth, J., Barriere, S. L., Kitt, M. M., Corey, G. R., for the FAST 2 Investigator Group, (2006). Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study. Antimicrob. Agents Chemother. 50: 862-867 [Abstract] [Full Text]  
  • Sun, H. K., Duchin, K., Nightingale, C. H., Shaw, J.-P., Seroogy, J., Nicolau, D. P. (2006). Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects. Antimicrob. Agents Chemother. 50: 788-790 [Abstract] [Full Text]  
  • Reyes, N., Skinner, R., Kaniga, K., Krause, K. M., Shelton, J., Obedencio, G. P., Gough, A., Conner, M., Hegde, S. S. (2005). Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 4344-4346 [Abstract] [Full Text]  
  • Madrigal, A. G., Basuino, L., Chambers, H. F. (2005). Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3163-3165 [Abstract] [Full Text]  
  • Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E. Jr., Gao, Q., Cass, R. T., Karr, D. E., Benton, B. M., Humphrey, P. P. (2005). Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 1127-1134 [Abstract] [Full Text]  
  • Shaw, J. P., Seroogy, J., Kaniga, K., Higgins, D. L., Kitt, M., Barriere, S. (2005). Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects. Antimicrob. Agents Chemother. 49: 195-201 [Abstract] [Full Text]  
  • Hegde, S. S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J., Kaniga, K., Pace, J., Thomas, R., Shaw, J.-P., Obedencio, G., Judice, J. K. (2004). Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria. Antimicrob. Agents Chemother. 48: 3043-3050 [Abstract] [Full Text]  
  • Stubbings, W. J., Bostock, J. M., Ingham, E., Chopra, I. (2004). Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 54: 139-143 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2004). In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp.. Antimicrob. Agents Chemother. 48: 2149-2152 [Abstract] [Full Text]  
  • King, A., Phillips, I., Kaniga, K. (2004). Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 53: 797-803 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pace, J. L.
Right arrow Articles by Kaniga, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pace, J. L.
Right arrow Articles by Kaniga, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»